この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2018/6/81 分で読めます
Development of Inhaled Antibacterial Drugs for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis; Public Workshop; Request for Comments
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public workshop entitled "Development of Inhaled Antibacterial Drugs for Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis." The purpose of the public workshop is to discuss the clinical trial design challenges and future considerations for inhaled antibacterial products to treat cystic fibrosis (CF) and non-CF bronchiectasis.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →